Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives [0.03%]
被选中进行医疗保险价格谈判的药品及其治疗替代品的价格基准
Inmaculada Hernandez,Emma M Cousin,Olivier J Wouters et al.
Inmaculada Hernandez et al.
Background: The Centers for Medicare and Medicaid Services (CMS) are currently negotiating prices with pharmaceutical manufacturers for the first 10 Part D drugs selected for Medicare drug price negotiation. Non-publicly ...
Impact of a tubeless, disposable insulin pump on emergency department visits and inpatient admissions among a Medicare population [0.03%]
一种新型无管可抛弃胰岛素泵对医疗保险人群急诊和住院的影响研究
Joseph E Biskupiak,Daniel L Carlow,Medha N Munshi
Joseph E Biskupiak
Background: A tubeless, disposable insulin pump (Omnipod DASH Insulin Management System, Insulet Corporation) has demonstrated improved glycemic outcomes for people with diabetes who require insulin. The impact of the sys...
Cost burden of cirrhosis and liver disease progression in metabolic dysfunction-associated steatohepatitis: A US cohort study [0.03%]
代谢功能障碍相关非酒精性肝炎所致肝硬化的经济负担及疾病进展：一项基于美国队列的研究
J Collin Fishman,Christina Qian,Yestle Kim et al.
J Collin Fishman et al.
Background: Metabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis, is characterized by fat accumulation and inflammation of the liver and may result in progression to cirrhosis and...
Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schizophrenia or schizoaffective disorder [0.03%]
关于首发每月一次利培酮酯长效肌肉注射抗精神病药物理赔被拒、撤回或支付后的精神分裂症和分裂情感障碍患者治疗模式及住院情况的分析
Carmela Benson,Charmi Patel,Inyoung Lee et al.
Carmela Benson et al.
Background: Once-monthly paliperidone palmitate (PP1M) is a long-acting injectable antipsychotic approved for the treatment of schizophrenia and schizoaffective disorder (SCA) in adults. ...
Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorder [0.03%]
注意缺陷多动障碍成人患者的共病精神障碍与其医疗资源利用和成本之间的关系
Jeff Schein,Martin Cloutier,Marjolaine Gauthier-Loiselle et al.
Jeff Schein et al.
Background: Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous condition with extensive psychiatric comorbidities. ADHD has been associated with substantial clinical and economic burden; however, little is...
Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it [0.03%]
生物仿制药在药房福利中的竞争：用进废退政策以维持市场竞争
Stanton R Mehr
Stanton R Mehr
Congress passed the Biologic Price Competition and Innovation Act of 2009, specifically to offer market competition as a counterweight to the rising costs of biologic medicines. As of April 15, 2024, 49 biosimilars have been approved by the...
US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies [0.03%]
美国商业健康计划在肺动脉高压疗法中的覆盖动态情况分析
Julia A Rucker,Molly T Beinfeld,Daniel E Enright et al.
Julia A Rucker et al.
Background: Health plan coverage is central to patient access to care, especially for rare, chronic diseases. For specialty drugs, coverage varies, resulting in barriers to access. Pulmonary arterial hypertension (PAH) is...
Productivity loss by cancer stage in patients newly diagnosed with hepatocellular carcinoma: A claims database analysis [0.03%]
基于理赔数据库分析的肝细胞癌新发患者的疾病负担（按临床分期）
Spencer J Cheng,Aasthaa Bansal,David L Veenstra
Spencer J Cheng
Background: New cancer diagnoses are associated with employment decrease, workplace absenteeism, and attributable costs to employers. Objective: ...
Projecting long-term clinical outcomes with larotrectinib compared with immune checkpoint inhibitors in metastatic nonsmall cell lung cancer and differentiated thyroid cancer [0.03%]
与免疫检查点抑制剂相比，Larotrectinib在转移性非小细胞肺癌和分化型甲状腺癌中的长期临床结局预测分析
Kangho Suh,Ashley Kang,Gilbert Ko et al.
Kangho Suh et al.
Background: Larotrectinib is approved for patients with advanced NTRK gene fusion-positive solid tumors. Prior studies demonstrated promising results with larotrectinib compared with other systemic therapy. However, compa...
Racial and ethnic disparities related to the Medicare Part D Medication Therapy Management Program [0.03%]
医疗保险部分D药物治疗管理方案中的种族差异问题
Audrey Allen,Anna Hung
Audrey Allen
Medicare's Part D Medication Therapy Management (MTM) programs serve approximately 4.5 million eligible beneficiaries. Prior research suggested that the thresholds to enter Part D MTM programs would disproportionately favor White beneficiar...